We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-With new Omicron case detected, UK awaits COVID booster advice

Sun, 28th Nov 2021 09:34

* UK wants to broaden booster campaign

* New measures are temporary

* Scotland also to introduce travel measures
(Adds new measures for some schoolchildren)

By Elizabeth Piper

LONDON, Nov 28 (Reuters) - Britain's health minister Sajid
Javid said on Sunday he expected to receive advice imminently on
whether the government can broaden a booster shot programme to
try to weaken the impact of the newly identified Omicron
coronavirus variant.

A day after Britain said it had detected two cases of the
variant, its health agency recorded a third - in a person who
was linked to travel to Southern Africa but had since left the
country after spending time in the capital London.

The government announced new measures on Saturday to try to
slow the spread of the variant, toughening rules for people
arriving into Britain and ordering the use of masks in retail
settings and on transport in England. Some schoolchildren will
also be required to wear face coverings in communal areas.

But ministers also want to ramp up the offer of booster
jabs, saying even if vaccines prove to be less effective against
Omicron, they should offer better protection against it and
reduce the number of hospitalisations and deaths.

"The other thing that still remains hugely important, but I
think it's fair to say now more important than it was before, is
our vaccination programme," Javid told Sky News.

"That is why I have also asked our expert advisers on
vaccines called JCVI (the Joint Committee on Vaccination and
Immunisation) to give me very quick advice on broadening,
boosting our booster programme, and I expect to get that advice
imminently."

Earlier this month, Britain expanded eligibility for booster
jabs to people in their 40s and also said children aged 16 and
17 would be able to receive a second dose following guidance
from the JCVI.

Scotland, where the government sets its own health rules,
already requires people to wear face coverings and work from
home if possible. First Minister Nicola Sturgeon told the BBC's
Andrew Marr show she would also bring in new rules for arrivals.

"I think we need to be open minded to doing anything
required to keep the population safe right now," she said.

BUYING TIME

The discovery of Omicron, dubbed a "variant of concern" last
week by the World Health Organization, has caused worry around
the world https://www.reuters.com/world/new-coronavirus-variant-omicron-keeps-spreading-australia-detects-cases-2021-11-28
that it could resist vaccinations and prolong the nearly
two-year COVID-19 pandemic.

Almost 145,000 people have died from COVID-19 in Britain,
with Johnson's government criticised for moving too slowly in
the early days of the pandemic. Since then, the government has
tried to react quickly to the appearance of new variants.

Javid said the new measures were needed to buy time for
experts to understand more about Omicron, which is likely to
have spread in Britain beyond the three cases so far detected.

Jenny Harries, chief executive of the UK's Health Security
Agency, said: "It is very likely that we will find more cases
over the coming days."

Paul Burton, chief medical officer at Moderna, said
that if a new vaccine was needed, "I think that's going to be
early 2022 before that’s really going to be available in large
quantities".

Javid said it was not as yet clear whether vaccines were
less effective against the variant.

"The point is the vaccines are still going to give you more
protection than otherwise," he said. "That is why the booster
programme is so important."
(Reporting by Elizabeth Piper, Editing by Louise Heavens, Mark
Heinrich, Raissa Kasolowsky and Catherine Evans)

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.